|
|
|
SENSEX
|
|
-364.20
|
-1.52%
|
23587.50
|
|
|
NIFTY
|
|
-1176.46
|
-1.49%
|
78041.59
|
|
|
Nasdaq
|
|
199.83
|
1.03%
|
19572.60
|
|
|
Nikkei 225
|
|
-111.68
|
-0.29%
|
38701.90
|
|
|
FTSE 100
|
|
-20.70
|
-0.26%
|
8084.60
|
|
|
|
|
|
|
|
|
YOU ARE ON
Equity
|
|
|
|
|
|
|
|
|
09-05-2024
|
|
|
Gland Pharma Limited has informed the Exchange about Schedule of meet |
|
|
|
09-05-2024
|
|
|
GLAND PHARMA LIMITED has informed the Exchange about Board Meeting to be held on 22-May-2024 to consider and approve the Yearly Audited Financial results of the Company for the period ended March 2024 and Dividend. |
|
|
|
07-05-2024
|
|
|
Gland Pharma Limited has informed the Exchange regarding a press release dated May 07, 2024, titled "Gland Pharma receives approval for Edaravone Injection ". |
|
|
|
07-05-2024
|
|
|
Gland Pharma Limited has informed the Exchange regarding a press release dated May 07, 2024, titled "Gland Pharma receives approval for Plerixafor for Injection ". |
|
|
|
29-04-2024
|
|
|
GLAND PHARMA LIMITED has informed the Exchange about Change in Directors/ Key Managerial Personnel/ Auditor/ Compliance Officer/ Share Transfer Agent |
|
|
|
29-04-2024
|
|
|
Gland Pharma Limited has informed the Exchange about change in Management |
|
|
|
29-04-2024
|
|
|
Gland Pharma Limited has informed the Exchange regarding Outcome of Board Meeting held on April 29, 2024. |
|
|
|
29-04-2024
|
|
|
Gland Pharma Limited has informed the Exchange regarding a press release dated April 29, 2024, titled "Gland Pharma receives approval for Cetrorelix Acetate for Injection". |
|
|
|
10-04-2024
|
|
|
Gland Pharma Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018 |
|
|
|
06-04-2024
|
|
|
Gland Pharma Limited has informed the Exchange regarding a press release dated April 06, 2024, titled "Gland Pharma receives approval for Eribulin Mesylate Injection". |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|